印度药企140亿美元收购美国药企 → 又一场“蛇吞象”?

蒲公英Ouryao
Feb 04

2026年1月,一则重磅传闻震动全球医药圈:印度最大药企太阳制药正评估以100亿至140亿美元全现金收购美国女性健康专科药企欧加隆(Organon)。若成真,这将是印度制药史上最大跨境并购,也是一场典型的“蛇吞象”式资本博弈。尽管双方尚未官宣,但其背后折射出的新兴市场药企全球化野心,值得中国同行深思。传闻并非空穴来风截至2026年2月初,该交易仍属市场传闻。但从业务逻辑看,高度契合。太阳制药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10